4 April 2013

ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Thursday 4^th April 2013. Ticky discussed the positive results of Starpharma’s Phase 2 prevention of recurrence BV trials.

 

 Watch the Interview (external link)

4 April 2013

AAP business reporter Trevor Chappell investigates Starpharma’s positive results for its Phase II trial of VivaGel to prevent recurring bacterial vaginosis (R-BV). The results demonstrated a reduced overall risk of R-BV.

"The commercial opportunity for recurrent BV is very attractive, with an estimated market of more than $1 billion," said Starpharma CEO Dr Jackie Fairley.

 

 Go to the article (external link)

14 March 2013

Herald Sun’s In The Black columnist, John Beveridge reported on Starpharma and its collaboration with Nufarm and Israel’s Makhreshim Agan, trading in Australia as Farmoz. These collaborations are a vote of confidence to the versatility of Starpharma’s dendrimer technology. "Dendrimers, nanoparticles that can greatly improve water solubility, are ideally suited to improving farming chemicals. In the case of weedkillers such as glyphosate, the addition of the right sort of dendrimer at the right levels can make the weedkiller much faster and more effective to use and able to be applied close to rain. For other agricultural chemicals the advantage is even greater, allowing the removal of dangerous solvents used to make theactive ingredient soluble and allowing the production of concentrates that are much easier to transport and can be mixed with water on site."

4 March 2013

Herald Sun reporters Brigid O’Connell, Lucie van den Berg and Grant McArthur featured Starpharma in a special report in The Herald Sun and The Australian online, examining cutting edge medical research being done in Melbourne.

"The home of corporate giants CSL, Mesoblast, Acrux, Biota and Starpharma, Melbourne also dominates in taking the laboratory to the marketplace: more than 85 products were on the market last year and dozens more were in trials in hopes of delivering the next generation of medical advances."

6 January 2013

The Herald Sun’s Chief Business Writer John Beveridge investigates some of the best strategies to make money on the stock market and profiles Starpharma as having potential, following the results of its Phase III trial for VivaGel as a treatment for BV:

All is not lost, though, because VivaGel still has potential to become the most effective treatment for the complaint and the company's dendrimer technology has numerous other lucrative applications.

1 November 2012

The Herald Sun’s Chief Business Writer John Beveridge reported on Starpharma’s announcement that a breast cancer study in mice which showed that adding dendrimers to the chemotherapy drug docetaxel led to drug concentrations within tumours of more than 40 times compared to using the drug alone.

John also profiles the technology platform – “Starpharma has built three exceptional opportunities, all of which promise significant revenue…” The sleeper in the Starpharma portfolio is using dendrimers to improve a range of agricultural chemicals, starting with the herbicide glyphosate.

29 October 2012

Respected Criterion columnist for The Australian Tim Boreham reported on promising results from Starpharma’s latest studies to improve leading cancer drug docetaxel, with its proprietary dendrimer technology. He also commented on Starpharma’s very promising VivaGel portfolio.

 

28 August 2012

Starpharma was featured on the back of its full year results with the well respected business commentator saying “Time to cross the fingers, keep the faith and buy.”

27 August 2012

Starpharma was featured by Bell Potter Healthcare Analyst Stuart Roberts as a top pick in the healthcare industry on Sky News.  Starpharma’s underlying technology was discussed and its application as a condom coating and treatment and preventative for bacterial vaginosis.  The segment featured a broader, positive outlook on the performance of the sector.

View the video (external link)

27 June 2012

Herald Sun Business Journalist John Beveridge examines Starpharma’s success in reaching commercial milestones and recruiting participants for its VivaGel trials in his In the Black column.

‘Three pivotal clinical trials are now almost completely stocked with test subjects, primarily to check the effectiveness of Starpharma's VivaGel at preventing and treating the common disorder bacterial vaginosis.

These trials are at the very sharp end of proceedings - phase two and phase three before the US Food and Drug Administration - and results should be in before Christmas.

That puts Starpharma chief executive Dr Jackie Fairley in a strong position to negotiate a lucrative deal next year with a large pharmaceutical partner to add marketing and distribution muscle to some excellent Australian-developed science.’

 

Go to the article (external link)